Global Rank
#13121
Country Rank
#202
Market Cap
551.22 M
Price
31.22
Change (%)
0.00%
Volume
43,732
Formycon AG's latest marketcap:
551.22 M
As of 06/08/2025, Formycon AG's market capitalization has reached $551.22 M. According to our data, Formycon AG is the 13121th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 551.22 M |
| Revenue (ttm) | 79.38 M |
| Net Income (ttm) | -143,184,393.2 |
| Shares Out | 17.66 M |
| EPS (ttm) | -8.19 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 05/15/2025 |
Market Cap Chart
Data Updated: 06/08/2025
Formycon AG's yearly market capitalization.
Formycon AG has seen its market value drop from €530 M to €483.8 M since 2020, representing a total decrease of 8.72% and an annual compound decline rate (CAGR) of 2.03%.
| Date | Market Cap | Change (%) |
|---|---|---|
| 06/08/2025 | €483.8 M | -48.4% |
| 12/30/2024 | €937.58 M | 3.65% |
| 12/29/2023 | €904.59 M | -30.88% |
| 12/30/2022 | €1.31 B | 100.81% |
| 12/30/2021 | €651.74 M | 22.97% |
| 12/30/2020 | €530 M |
Company Profile
About Formycon AG
Formycon AG is a biotechnology company specializing in the development of biosimilar drugs, operating primarily in Germany and Switzerland.
Key Products & Pipeline
- FYB201 – A biosimilar candidate for Lucentis, used in treating retinal diseases such as neovascular age-related macular degeneration and diabetic macular edema. Marketed under various names including Ranivisio, Ongavia, and Cimerli.
- FYB202 – A biosimilar candidate for Stelara, targeting psoriasis, Crohn’s disease, and ulcerative colitis. Phase III clinical trials completed.
- FYB203 – A biosimilar candidate for Eylea, designed for ophthalmology-related diseases like neovascular age-related macular degeneration. Phase III clinical trials completed.
- FYB206 – A biosimilar candidate for Keytruda, focused on immuno-oncology treatments.
- FYB207 – An antiviral drug acting as a SARS-CoV-2 blocker, developed for COVID-19 treatment.
Company Background
Originally founded in 1999 as Nanohale AG, the company rebranded to Formycon AG in 2012. Its headquarters are located in Planegg, Germany.
Frequently Asked Questions
-
What is Formycon AG's (ETR-FYB) current market cap?As of 06/08/2025, Formycon AG (including the parent company, if applicable) has an estimated market capitalization of $551.22 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Formycon AG (ETR-FYB) rank globally by market cap?Formycon AG global market capitalization ranking is approximately 13121 as of 06/08/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.